Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast-Enhanced Ultrasound for RCC Cryoablation Evaluation
NCT02671552Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren protein type a in renal cell carcinoma (RCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Sensitivity, Specificity and 3 more. Planned start Jan 2013; status: withdrawn.
02
Drugs
perflutren protein type a
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02671552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671552.